The medical devices sector is typified by frequent change and innovation, in response to problems and issues faced by the healthcare industry. As a result, the sector has seen the emergence of several start-up medtech companies offering disruptive, cutting-edge solutions. Most of these are private companies, where data such as revenue is frequently not disclosed. National estimates for Gramedica sales in the US from 2017 to 2023, as well as year-on-year growth rates, can be viewed in GlobalData’s micro revenue report. Buy the report here.
GraMedica LLC (GraMedica) is a medical device company that provide development and provision of innovative solutions for foot and ankle instability. The company products include HyProCure II, an FDA-cleared sinus tarsi stent, Opti-Toe, a device for toe reconstruction, Stevens Tenotomy Scissors, Graham Decompression Scissors, osteo-WEDGE, a bone locking system, and various educational tools like AlignMyFeet Magnetic Foot Models and Talus and Calcaneous Bone Models. It markets its products under the brands HyProCure. GraMedica is headquartered in Macomb, Michigan, USA.
The key metrics of Gramedica related to marketed and pipeline products, ongoing clinical trials, active jobs and publications from 2023 are shown below:
As Gramedica is a privately held company, it is not required to disclose its financial information and there is no stock listed on an exchange. GlobalData has access to a proprietary data set containing invoice data from over 2,600 healthcare institutions in the US and is therefore able to use estimations of a company’s revenue and growth to value private companies such as Gramedica.
For a detailed understanding of the performance of Gramedica, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.